Tableaux’s Charles River Laboratories CRL Stock Holding History

Tableaux’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,672	Closed	-$252K	–	119
2025 Q1	$252K	Buy	+1,672	New	+$280K	0.18%	74

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Tableaux's CRL Position: Q2 2025 in Review

Tableaux sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 1,672 shares — an estimated $252K sold.

Tableaux first reported a position in CRL in Q1 2025 and held it in 1 quarter. The position peaked at $252K in Q1 2025. 518 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Tableaux reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Tableaux sold 1,672 Charles River Laboratories shares in Q2 2025, an estimated $252K.
Tableaux first reported a position in Charles River Laboratories in Q1 2025 and held it in 1 quarter.
Tableaux's Charles River Laboratories position peaked at $252K in Q1 2025.
518 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Tableaux's 13F filing for Q2 2025, filed 12 Aug 2025.